After Hours Summary: AHH +3.5% on SmallCap 600 addition news, SAIC -10% following earnings/guidance, SYNA -3% on acquisition news/updated guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to news: CLNT +17.3% (enters into exclusive discussions with ECrent Capital Holdings Limited), AHH +3.5% (will replace Pinnacle Financial Partners in the S&P SmallCap 600), CGIX +2.6% (10% owner/Director disclosed purchase of 100K shares worth total of $375K), IMAX +1.3% (ticking higher; authorizes new $200 mln share-repurchase program and cost-reduction initiative), DVAX +1.3% (continued strength), CHRS +1.1% (confirms that on June 9, the Patent Trial and Appeal Board ruled in favor of the Company's petitions for Inter Partes Review of ABBV U.S. 9,017,680 and 9,073,987), ADMS +0.8% (Adamas Pharmaceuticals announces that results of its Phase 3 EASE LID clinical trial of ADS-5102 were published online in JAMA Neurology; placebo-controlled phase 3 trial demonstrated that ads-5102 significantly reduced both dyskinesia and off time at six months in Parkinson's Disease patients with levodopa-induced dyskinesia), RE +0.5% (light volume; to join S&P 500), PNFP +0.5% (will replace Everest Re Group in the S&P MidCap 400; also shareholders voted to approve merger proposals - transaction is expected to close in the second quarter)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: SAIC -9.7%
Companies trading lower in after hours in reaction to news: REED -14.8% (COO Mark Beaton resigned effective close of business on June 19, 2017; also files for offering of 2,550,000 shares of common stock by holders, consisting of 1,133,333 shares issuable upon conversion of a promissory note and 1,416,667 shares issuable upon the exercise of 2017-2 warrants), XLRN -5.1% (announces top-line results from DART Phase 2 Study of dalantercept in advanced renal cell carcinoma; to discontinue development) SYNA -3% (Synaptics to acquire voice and audio processing solutions company Conexant Systems and Multimedia Solutions Business from MRVL; updates guidance), FR -1.8% (commenced 2.56 mln share common stock offering), HCLP -1.6% / EMES -1.5% (attributed to SLCA plant plans), MRK -0.6% (updates on two studies of KEYTRUDA in multiple myeloma; to pause new enrollment on KEYNOTE-183 and KEYNOTE-185 following the external Data Monitoring Committee recommendation)